Skip to content

Neuronavigation based TMS therapy for non suicidal self injury using OFC-V1 neural pathway Clinical study on adolescent depression

Neuronavigation based TMS therapy for non suicidal self injury using OFC-V1 neural pathway Clinical study on adolescent depression

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096122
Enrollment
Unknown
Registered
2025-01-17
Start date
2025-02-20
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

Control group (pseudo-stimulation group):RMT low-frequency pseudo stimulus
stimulated group:rTMS treatment

Sponsors

Huzhou Third Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 28 Years

Inclusion criteria

Inclusion criteria: 1.The patient (or their legal representative/guardian) signs an informed consent form; 2.14 <= Age <=28 years old, gender not limited; 3.Adopting a simplified International Neuropsychiatric Interview (MINI) that meets the diagnostic criteria for DSM-V depressive episodes; 4.Young's Mania Scale (YMRS) <= 6 points; 5.12 points <= Montgomery Depression Scale (MARDS) < 30 points; 6.Right-handed hand; 7.have completed more than 9 years of compulsory education.

Exclusion criteria

Exclusion criteria: 1.History of cognitive loss due to organic brain disease or head trauma; 2.Any significant or unstable history of cardiovascular, respiratory, neurological (including epilepsy or obvious cerebrovascular disease, traumatic brain injury), renal, liver, endocrine or immune diseases, or organic diseases causing anxiety, depression, or other related conditions, or current infection, trauma, etc; 3.Any contraindications of MRI or abnormal brain structure detected by magnetic resonance examination; 4.Individuals with hearing problems (unable to hear or understand the examiner's speech clearly during normal conversation) and vision problems; 5.History of abuse and dependence on psychoactive substances; 6.Long term use of anticholinergic drugs or recent use of anti-inflammatory drugs; 7.Pregnant, lactating women or those planning to conceive; 8.Serious suicidal ideation and behavior or MARDS >= 30 points; 9.Patients who receive ECT or rTMS treatment within six months.

Design outcomes

Primary

MeasureTime frame
Montgomery Depression Rating Scale,MARDS;Magnetic resonance data and near-infrared;Adolescent Non-suicidal Self-injury Assessment Questionnaire,ANSAQ;Hamilton Depression Rating Scale (HAMD);Hamilton Anxiety Scale;

Countries

China

Contacts

Public ContactShiliang Wang

Huzhou Third Municipal Hospital

93889766@qq.com+86 572 2129892

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026